Pfizer said Friday that its experimental antiviral pill for COVID–19 cut rates of hospitalization and death by nearly 90% in high-risk adults.
Most COVID-19 treatments currently require an IV or injection. Competitor Merck’s COVID-19 pill is under review at the Food and Drug Administration already after showing strong initial results. The United Kingdom became the first country to OK it on Thursday.
Independent experts recommended halting the company’s study based on the strength of its results. Pfizer said it will ask the FDA and other regulators to authorize its pill as soon as possible.
Researchers worldwide have been racing to find a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital.